Ropes & Gray advised Sanofi on the transaction, and Goodwin Procter advised Vigil Neuroscience. Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in Vigil...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Prime Medicine and Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction, while Davis Polk & Wardwell...
You must be a Standard 1 Year member to access this content.
Goodwin advised Isomorphic Labs on its strategic research collaboration with Novartis. Isomorphic Labs has signed a strategic research collaboration with Novartis to discover small molecule therapeutics against...
You must be a Standard 1 Year member to access this content.
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
You must be a Standard 1 Year member to access this content.
Goodwin advised Human Immunology Biosciences (HI-Bio) on the round. Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs),...
You must be a Standard 1 Year member to access this content.
Goodwin advised SpringWorks Therapeutics, Inc. on the offering. American precision medicine company SpringWorks Therapeutics (Nasdaq: SWTX) has closed a public offering of 10,905,171 shares of its common...
You must be a Standard 1 Year member to access this content.
Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aditum Bio and its new portfolio company, Celexor Bio, in an in-licensing transaction with Inmagene Biopharmaceuticals. Celexor Bio is being formed in connection...
You must be a Standard 1 Year member to access this content.
Goodwin advised Mariana Oncology on the fundraising. Mariana Oncology Inc. announced its oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion, and...
You must be a Standard 1 Year member to access this content.
Goodwin advised Rapport Therapeutics on the fundraising. Rapport Therapeutics announced the completion of its $150 million in Series B funding. Led by Cormorant Asset Management, the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
You must be a Standard 1 Year member to access this content.
Goodwin advised K36 Therapeutics on the financing. K36 Therapeutics announced a $70M Series B financing. The round was led by Nextech Invest, Ltd, a precision medicine focused...
You must be a Standard 1 Year member to access this content.
